BR112017013956B8 - Proteínas de fusão de citocinas - Google Patents
Proteínas de fusão de citocinasInfo
- Publication number
- BR112017013956B8 BR112017013956B8 BR112017013956A BR112017013956A BR112017013956B8 BR 112017013956 B8 BR112017013956 B8 BR 112017013956B8 BR 112017013956 A BR112017013956 A BR 112017013956A BR 112017013956 A BR112017013956 A BR 112017013956A BR 112017013956 B8 BR112017013956 B8 BR 112017013956B8
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- cytokine fusion
- nucleic acid
- acid molecules
- molecules encoding
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 5
- 108090000695 Cytokines Proteins 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/050682 WO2016112983A1 (en) | 2015-01-15 | 2015-01-15 | Cytokine fusion proteins |
EPPCT/EP2015/050682 | 2015-01-15 | ||
PCT/EP2016/050773 WO2016113395A1 (en) | 2015-01-15 | 2016-01-15 | Cytokine fusion proteins |
Publications (4)
Publication Number | Publication Date |
---|---|
BR112017013956A2 BR112017013956A2 (pt) | 2018-01-16 |
BR112017013956A8 BR112017013956A8 (pt) | 2019-04-02 |
BR112017013956B1 BR112017013956B1 (pt) | 2024-01-23 |
BR112017013956B8 true BR112017013956B8 (pt) | 2024-02-06 |
Family
ID=52394237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017013956A BR112017013956B8 (pt) | 2015-01-15 | 2016-01-15 | Proteínas de fusão de citocinas |
Country Status (11)
Country | Link |
---|---|
US (2) | US10301368B2 (pt) |
EP (1) | EP3245223B1 (pt) |
JP (1) | JP6813491B2 (pt) |
CN (2) | CN113801241A (pt) |
AU (1) | AU2016207955B2 (pt) |
BR (1) | BR112017013956B8 (pt) |
CA (1) | CA2971950A1 (pt) |
HK (2) | HK1246315A1 (pt) |
MX (2) | MX2017009153A (pt) |
NZ (1) | NZ733266A (pt) |
WO (2) | WO2016112983A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
WO2018027025A1 (en) * | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
EP3585418A4 (en) * | 2017-02-27 | 2020-11-25 | Shattuck Labs, Inc. | TIGITE AND LIGHT BASED CHIMERIC PROTEINS |
UY37621A (es) * | 2017-02-28 | 2018-09-28 | Sanofi Sa | Arn terapéutico que codifica citoquinas |
AU2018247931B2 (en) * | 2017-04-06 | 2022-03-03 | Universität Stuttgart | Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity |
EP3648786A4 (en) * | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES |
AU2019206573A1 (en) * | 2018-01-10 | 2020-07-16 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
AU2019276372A1 (en) | 2018-06-01 | 2020-12-24 | Evotec International Gmbh | Combination therapy for treating hepatitis B virus infection |
AU2019362902A1 (en) * | 2018-10-17 | 2021-04-29 | Albert Einstein College Of Medicine | Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc) |
WO2021072127A2 (en) * | 2019-10-08 | 2021-04-15 | Fred Hutchinson Cancer Research Center | Engineered trimeric cd70 proteins and uses thereof |
CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
CN111018999B (zh) * | 2019-12-05 | 2022-07-12 | 沣潮医药科技(上海)有限公司 | 二聚体免疫融合蛋白、药物组合物和用途 |
WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19963859A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
DE102004014983A1 (de) * | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
DK2604693T3 (en) * | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
EP2406388B1 (en) * | 2009-03-13 | 2016-09-28 | The Trustees Of The University Of Pennsylvania | Ox40/trail fusion proteins |
WO2013156054A1 (en) | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
CN104244708B (zh) * | 2012-04-24 | 2016-09-14 | 北欧机械制造鲁道夫巴德尔有限及两合公司 | 鱼围栏及鱼积聚器 |
AU2014233114B2 (en) * | 2013-03-15 | 2018-03-08 | Richard S. Kornbluth | Composition comprised of antigen linked to a TNF SuperFamily ligand |
-
2015
- 2015-01-15 WO PCT/EP2015/050682 patent/WO2016112983A1/en active Application Filing
-
2016
- 2016-01-15 CN CN202111042819.0A patent/CN113801241A/zh active Pending
- 2016-01-15 EP EP16700745.9A patent/EP3245223B1/en active Active
- 2016-01-15 WO PCT/EP2016/050773 patent/WO2016113395A1/en active Application Filing
- 2016-01-15 AU AU2016207955A patent/AU2016207955B2/en active Active
- 2016-01-15 US US15/543,566 patent/US10301368B2/en active Active
- 2016-01-15 MX MX2017009153A patent/MX2017009153A/es unknown
- 2016-01-15 CA CA2971950A patent/CA2971950A1/en active Pending
- 2016-01-15 BR BR112017013956A patent/BR112017013956B8/pt active IP Right Grant
- 2016-01-15 JP JP2017537463A patent/JP6813491B2/ja active Active
- 2016-01-15 NZ NZ733266A patent/NZ733266A/en unknown
- 2016-01-15 CN CN201680005778.9A patent/CN107428842B/zh active Active
-
2017
- 2017-07-12 MX MX2021010668A patent/MX2021010668A/es unknown
-
2018
- 2018-05-03 HK HK18105702.8A patent/HK1246315A1/zh unknown
- 2018-05-03 HK HK18105729.7A patent/HK1246316A1/zh unknown
-
2019
- 2019-04-03 US US16/374,503 patent/US10808019B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016113395A1 (en) | 2016-07-21 |
NZ733266A (en) | 2022-04-29 |
AU2016207955A1 (en) | 2017-07-20 |
BR112017013956A8 (pt) | 2019-04-02 |
US10808019B2 (en) | 2020-10-20 |
BR112017013956B1 (pt) | 2024-01-23 |
CA2971950A1 (en) | 2016-07-21 |
JP2018503379A (ja) | 2018-02-08 |
EP3245223A1 (en) | 2017-11-22 |
US10301368B2 (en) | 2019-05-28 |
EP3245223B1 (en) | 2020-03-04 |
JP6813491B2 (ja) | 2021-01-13 |
HK1246316A1 (zh) | 2018-09-07 |
WO2016112983A1 (en) | 2016-07-21 |
US20180002392A1 (en) | 2018-01-04 |
MX2021010668A (es) | 2021-09-28 |
MX2017009153A (es) | 2018-02-01 |
CN107428842B (zh) | 2021-10-01 |
HK1246315A1 (zh) | 2018-09-07 |
CN113801241A (zh) | 2021-12-17 |
BR112017013956A2 (pt) | 2018-01-16 |
CN107428842A (zh) | 2017-12-01 |
AU2016207955B2 (en) | 2020-05-28 |
US20190276511A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017013956B8 (pt) | Proteínas de fusão de citocinas | |
CY1124740T1 (el) | Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης | |
CY1123642T1 (el) | Αντισωματα enanti-pd-1 | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CO2018002703A2 (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos | |
CL2017002820A1 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
BR112016015105A2 (pt) | Conjugados var2csa-droga | |
BR112018008051A2 (pt) | vacinas de ácido nucleico para vírus de varicella zoster (vzv) | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
DK2831241T3 (da) | Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression. | |
BR112018012262A2 (pt) | composições de interleucina-15 e seus usos | |
EA201492221A1 (ru) | Полипептиды, имеющие активность трансгалактозилирования | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
PE20160528A1 (es) | Anticuerpos | |
BR112017013576A2 (pt) | produção melhorada de lipídios de núcleo em leveduras oleaginosas | |
UY34373A (es) | Moléculas de ácido nucleico que se dirigen a pp1-87b y confieren resistencia a plagas de coleópteros. | |
CL2013003821A1 (es) | Polinucleótido que codifica un polipéptido receptor pyr/pyl mutado, casete de expresión que comprende dicho ácido nucleico, y método para producir planta con actividad inhibida de la proteína fosfatasa tipo 2 en ausencia de ácido abscísico. | |
AR090668A1 (es) | Anticuerpo anti-adamts-5, derivados y usos del mismo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE) , UNIVERSIT |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: UNIVERSITAET STUTTGART (DE) ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GGMBH (DE) ; BIONTECH SE (DE) |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2768 DE 23/01/2024, QUANTO AO ITEM (73) ENDERECO DO TITULAR. |